

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7718064
<b>Application Number:</b>	09993647
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1010
<b>Title of Invention:</b>	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
<b>First Named Inventor/Applicant Name:</b>	Bernd Riedl
<b>Customer Number:</b>	23599
<b>Filer:</b>	Csaba Henter/Caitlin Sickler
<b>Filer Authorized By:</b>	Csaba Henter
<b>Attorney Docket Number:</b>	BAYER 18A
<b>Receipt Date:</b>	01-JUN-2010
<b>Filing Date:</b>	27-NOV-2001
<b>Time Stamp:</b>	13:31:18
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P32- CampbellIncreasingComplexity ofRasSignaling.pdf	2424350 a9005795d543aa40f07cec14e63d4b28e971cd17	no	19

### Warnings:

### Information:

2	NPL Documents	P33-CANCER-WEEKLY.pdf	140661	no	1
			3232e036f48ae770312cdd40a12c4cc85e8c3833		
Warnings:					
Information:					
3	NPL Documents	P34-CanettaCarboplatin-CurrentStatusAndFutureProspects.pdf	3826172	no	45
			68cb8b378f1b057d3ed83f5db47e22ebc356dddb		
Warnings:					
Information:					
4	NPL Documents	P34a-CaponigroetalEpidermalGrowthFactor.PDF	1083691	no	12
			cb0da2475eb186592ee47a8decdb95aadd78f602		
Warnings:					
Information:					
5	NPL Documents	P35-CareyetalPartAStructureandMechanisms.pdf	471534	no	12
			e37a47031d1f732b52697172521055ce78a92583		
Warnings:					
Information:					
6	NPL Documents	P36-Carlingetal1-3-Cyanobenzylpiperidin-4-yl-5-methyl-4-phenyl-1-3.pdf	1040304	no	10
			0bbeed7391a54a281fa7114b24c8446f06e599bc		
Warnings:					
Information:					
7	NPL Documents	P37-CARLOMAGNOETALInhibitionOfnconogenicRET.pdf	1069541	no	9
			4ad37714335cf38ca3ad2d3693398db4c80fc33d		
Warnings:					
Information:					
8	NPL Documents	P37a-CarneyetalClinicalBreastCancer.pdf	1138273	no	12
			5c6566aff12dd1c0b8c0259f5580f68e06b52364		
Warnings:					
Information:					
9	NPL Documents	P38-CarteretalAntitumorEfficacy.pdf	167798	no	1
			7c2cec57211e6d7473851930bcb3a329f1c591dc		
Warnings:					
Information:					
10	NPL Documents	P39-CARTER-ET-AL-ChemotherapyofCancer.pdf	136044	no	3
			5a19a450599c3aaa0245938a96f4db2087c09231		
Warnings:					
Information:					

11	NPL Documents	P40-CARTERETAL-SorefenibNonSmallCellLung.pdf	169623 f5ae266e2e27265c039079605b12c8ae22d2566a	no	2
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	P41-ChangBAY43-9006SorafenibInhibitsEctopicSCandOrthotopicGrowthofaMurine.pdf	73262 b459963e6d62393827dc61063921213bbd2088f2	no	1
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	P42-ChangetalSorafenibInhibitsTumorGrowth.pdf	1922377 831604d6f312d7c6609a9fc5d26ec8393a431a9c	no	14
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	P43-ChenetalRoleofRegulatoryElements.pdf	1457296 ac3054b2e2e0bc696c60ac5a80580ef4c186f8ee	no	13
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	P44-ChenetalSuppresionofJapaneseEncephalitis.pdf	847967 bb6ae1b3ba6d270c849107bb032289078f66406b	no	9
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	P44a-Chen-et-al-Clin-Cancer-Res-v5-n6-p1369.pdf	5134664 fd2f7fc86a01f75334ebf09ade25f5c2bb96a8c1	no	11
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	P45-Chialdaetal-RespiratoryResearch.pdf	1531043 7ea2793b918dd0ad134a01368ded0010ff545ac9	no	19
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	P45a-Chin-et-al-Eur-J-Surg--Oncol-v29-p497.pdf	495783 adebf33c0baed130c2e29c0972bcd524ea14705ee	no	9
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	P46-CHOI-Imatinib-ResistantCellLinesareSensitivetotheRAFInhibitorBAY.pdf	285856 ce5d049ac10d061f9da655ce2af58f2fa404810b	no	1
<b>Warnings:</b>					
<b>Information:</b>					

20	NPL Documents	P46a- ChoongetalForthcomingRecep torTyrosineKinase.PDF	442002  54975ac2758bf361df9e8811de8d4d0ccbb e1562	no	5
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			23858241		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  <b>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</b></p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  <b>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</b></p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  <b>If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</b></p>					